★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Edwards Lifesciences Corporation (EW) Moat Analysis
Edwards Lifesciences Corporation
EW · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Edwards Lifesciences is focused on TAVR, transcatheter mitral and tricuspid therapies, and surgical structural heart. Its strongest advantages are extensive long-term clinical evidence, product trust, and procedure-specific training around SAPIEN, plus RESILIA’s demonstrated 10-year surgical-valve durability. EVOQUE has a modest early approval and evidence lead in transcatheter tricuspid replacement, but that market remains young. Regulation, quality systems, generic IP disclosures, and single-source supply requirements are important industry constraints, not differentiated Edwards moats.
Primary segment
Transcatheter Aortic Valve Replacement (TAVR)
Market structure
Oligopoly
Market share
60%-73% (estimated)
HHI: —
Coverage
3 segments · 5 tags
Updated 2026-07-12
Segments
Transcatheter Aortic Valve Replacement (TAVR)
Transcatheter aortic valve replacement (TAVR) devices
Revenue
74%
Structure
Oligopoly
Pricing
moderate
Share
60%-73% (estimated)
Peers
Transcatheter Mitral and Tricuspid Therapies (TMTT)
Transcatheter mitral and tricuspid valve repair and replacement devices
Revenue
9.1%
Structure
Competitive
Pricing
weak
Share
—
Peers
Surgical Structural Heart
Surgical heart valves and structural heart repair products
Revenue
17%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Transcatheter Aortic Valve Replacement (TAVR)
Transcatheter aortic valve replacement (TAVR) devices
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Long-term SAPIEN clinical evidence and stable pricing support physician preference in a high-stakes implant decision, though large competitors offer credible alternatives.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Competitor outcomes data shifting preference in key sub-populations
- Pricing pressure from hospital cost containment and tenders
- New entrants expanding choice and reducing perceived differentiation
Leading indicators
- U.S. and EU procedure share trends for major TAVR platforms
- Guideline positioning and pivotal trial readouts (Edwards and competitors)
- ASP/price realization commentary and gross margin trajectory
Counterarguments
- Hospitals can dual-source valves; switching is feasible with incremental training
- Clinical outcomes can trump incumbent brand if competitors show superior results
Training Org Change Costs
Demand
Training Org Change Costs
Strength
Durability
Confidence
Evidence
Procedure support, training, and ongoing field-clinical presence embed Edwards into structural heart programs and increase friction to switching platforms.
Training Org Change Costs moat: definition, examples, and stocks
Erosion risks
- Standardization of training across vendors reducing differentiation
- Hospital staff turnover reducing accumulated know-how advantage
Leading indicators
- Number of active TAVR centers and center expansions
- Changes in field support intensity or staffing
- Competitor training/proctoring programs scaling
Counterarguments
- Structural heart teams already manage multiple device vendors; training may not be a binding constraint
- Procurement decisions can override clinician preference in cost-focused environments
Transcatheter Mitral and Tricuspid Therapies (TMTT)
Transcatheter mitral and tricuspid valve repair and replacement devices
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
EVOQUE’s first approval and accumulating outcomes data provide an early time-to-market advantage in tricuspid replacement, but the category is young and competitors can catch up.
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Competitors achieving comparable approvals with differentiated devices
- Adverse trial outcomes or slower-than-expected adoption
- Reimbursement or guideline constraints
Leading indicators
- FDA/CE approvals and label expansions in mitral/tricuspid categories
- Procedure volume trends for tricuspid replacement and repair
- Post-market safety signals and registry outcomes
Counterarguments
- Category is crowded; incumbents in mitral repair (notably ABT) have strong positions
- Physician preference may fragment across multiple approaches (repair vs replacement)
Surgical Structural Heart
Surgical heart valves and structural heart repair products
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
Prospective 10-year RESILIA durability data support surgeon confidence and product preference in a long-cycle implant market.
Brand Trust moat: definition, examples, and stocks
Erosion risks
- Long-term durability data for competitors narrowing perceived gap
- Shift of eligible patients from surgical to transcatheter approaches
- Hospital purchasing consolidation increasing price competition
Leading indicators
- Long-term durability outcomes published in peer-reviewed venues
- Surgical procedure volumes vs transcatheter substitution trends
- Competitive wins/losses in major health systems and buying groups
Counterarguments
- Surgical valve market includes large diversified competitors with deep relationships
- Durability claims can be matched over time as competitors accumulate data
Evidence
The Edwards SAPIEN family of valves remains a best-in-class therapy for lifetime management of patients with severe aortic stenosis.
Supports brand/trust moat via product positioning and implied physician confidence.
Edwards’ global competitive position in the first quarter increased slightly year-over-year... Average selling prices were stable globally.
Current commercial evidence is consistent with sustained physician preference and pricing stability.
Field clinical specialists routinely attend procedures... enabling physicians and staff to reach expert proficiency.
Indicates embedded training/proctoring model that increases organizational switching costs.
Edwards Lifesciences is currently the market leader and holds over 60% of the US TAVR market.
Provides a floor (>60%) based on GlobalData's invoicing database commentary.
The survey suggests Edwards will control 72.3% of the U.S. TAVR market in 2025.
Upper-bound anchor from a Leerink Partners-commissioned cardiologist survey.
Showing 5 of 10 sources.
Risks & Indicators
Erosion risks
- Competitor outcomes data shifting preference in key sub-populations
- Pricing pressure from hospital cost containment and tenders
- New entrants expanding choice and reducing perceived differentiation
- Standardization of training across vendors reducing differentiation
- Hospital staff turnover reducing accumulated know-how advantage
- Competitors achieving comparable approvals with differentiated devices
Leading indicators
- U.S. and EU procedure share trends for major TAVR platforms
- Guideline positioning and pivotal trial readouts (Edwards and competitors)
- ASP/price realization commentary and gross margin trajectory
- Number of active TAVR centers and center expansions
- Changes in field support intensity or staffing
- Competitor training/proctoring programs scaling
Research EW elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.